1. Midlands and East
Regional Industry Group
Richard Price, Regional Director for the West Midlands and Wales | Pfizer,
Chair | ABPI Regional Industry Group Midlands & East

2. Our aim today...
Share progress of the RIG since
launch and outline the future
direction
Role of background of ABPI
Engage with some colleagues
from the NHS – their
expectations from joint working?
Participate in a workshop aimed
at exploring innovative
approaches to joint working
Further reading
http://www.abpi.org.uk/our-work/news/2012/Pages/140512.aspx

3. IHW - Accelerating adoption and diffusion in the NHS
• Innovation, Health and
Wealth report was
published on 5th
December 2011
• ABPI warmly welcomed
the report as a
significant step forward
to support adoption and
diffusion of innovative
medicines across the
NHS
“..simply doing more of what we have always
done is no longer an option. We need to do
things differently. We need to radically
transform the way we deliver services.” Sir
David Nicholson, Chief Executive of the
NHS in England. (p4)
“We need to create a system for
innovation that continually
scans for new ideas, and takes
them through to widespread
use. In order to do this we must
work with industry, academia,
staff and patients, to set an
agenda for change and
delivery.”

4. Choluteca Bridge

6. Both the NHS and pharma have their challenges….
• The famously quoted “Nicholson challenge” actually dates back to a McKinsey report
in 2009 that explored the efficiency savings possible if the NHS budget had zero
growth. So as e.g. life expectancy increases, we have more frail elderly, we use more
technology – the spend would be expected to increase ~5%/ annum, as in previous
years. But this is no longer the case – hence the £20bn figure - and £50bn in future
years http://tinyurl.com/cajfc83
• Care scandals – Mid Staffs, Winterbourne and many others – Don Bewick, the national
quality „tsar‟ calling this “the normalisation of deviance”. So quality needs to
dramatically improve while budgets shrink – and we have just had an NHS
reorganisation that‟s “so big, you can see it from space”
• As for pharma – are the days of blockbusters over? R&D is getting harder, development
is often through acquisition and industry is a global business. Other issues include
patent expiry, changing business models, biotech companies – we work in a rapidly
shifting environment

7. Other national policy drivers
• Academic Health Science Networks
• Formularies Good Practice Guide
• The changing role of NICE
• Medicines optimisation guidance
• Changes to the standard national contract
• CCG legal duty to innovate
• NHS Mandate
• NHS Constitution
....... A ‘perfect storm’

8. Regional Industry Groups
• Summer 2012, we wrote to all member company GMs, asking for nominations to sit
on our Regional Industry Groups = RIGs
• Individuals had to have at least 5+ years of market access experience at a senior
level, and be prepared to take an industry perspective
• The ABPI funds these groups – they are not ‘pay to play’
• Each region was allocated 12 – 15 places and the first meeting took place in the
South in November 2012
• We elected a Chair – Richard Price, Pfizer – and a deputy Chair – Charlotte Clarke,
GSK
• The ABPI Regional Manager organises all the meetings and provides secretariat

9. It’s good to work together….
to invest a £23B NHS budget wisely
Popn 15,649,000

10. Progress so far...
Foundation
• Agreed terms of
reference and
established RIG as an
industry reference
group
• Explored expectations
and concerns
• Respecting the needs
of all organisations
• Common aim
Engagement
• Project prioritisation
template
• Comms and
Engagement Strategy
• Establishing good
links with the three
Midlands and East
AHSNs
• Proposals for joint
working reviewed
using the 7 step tool
Prioritisation
• CCG mapping with a
real drive to build a
connection with hard
to reach organisations
• Events in place with
NHS to identify joint
working opportunities

11. Task and Finish Groups
•CCG Workshops
•Adherence to antipsychotics in severe mental illness
•West Midlands regional asthma strategy
•NOACs uptake pilot
•Support for diabetes networks
•Strategy for innovation health and wealth